Novartis' trial results are impacting Royalty Pharma's investment decisions.

1 report, 1 independent Updated Sep 5

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Novartis Royalty Pharma

Keep exploring

Part of

Royalty Pharma outperformed the market so far this year, based on data from August 6, 2025. All 1 developments

The entities involved

Novartis
Swiss-American multinational pharmaceutical corporation
- Novartis developed a Bruton's tyrosine kinase inhibitor, with Heinz Wiendl being a professor at the University of Freiburg.Sat 05:09
Royalty Pharma
biopharmaceutical company based in New York City
- Royalty Pharma is investing in drug makers and developers to diversify its portfolio in the biotech sector.Sun 15:42

Related events

FDA endorsed broader use of a Lilly medicine, and Abogen furnished Novartis with RNA technology.Oct 15

Coverage

Newest first; wire copies grouped

Sep 5finanznachrichten.de